IRIS Accounts Production v26.1.0.640 15251696 Board of Directors 1.10.24 30.9.25 30.9.25 18.5.26 0 0 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 15251696 2024-09-30 15251696 2025-09-30 15251696 2024-10-01 2025-09-30 15251696 2023-10-31 15251696 2023-11-01 2024-09-30 15251696 2024-09-30 15251696 ns15:EnglandWales 2024-10-01 2025-09-30 15251696 ns14:PoundSterling 2024-10-01 2025-09-30 15251696 ns10:Director1 2024-10-01 2025-09-30 15251696 ns10:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 15251696 ns10:SmallEntities 2024-10-01 2025-09-30 15251696 ns10:Audited 2024-10-01 2025-09-30 15251696 ns10:SmallCompaniesRegimeForDirectorsReport 2024-10-01 2025-09-30 15251696 ns10:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 15251696 ns10:FullAccounts 2024-10-01 2025-09-30 15251696 ns10:OrdinaryShareClass1 2024-10-01 2025-09-30 15251696 ns10:Director2 2024-10-01 2025-09-30 15251696 ns10:CompanySecretary1 2024-10-01 2025-09-30 15251696 ns10:RegisteredOffice 2024-10-01 2025-09-30 15251696 ns5:CurrentFinancialInstruments 2025-09-30 15251696 ns5:CurrentFinancialInstruments 2024-09-30 15251696 ns5:ShareCapital 2025-09-30 15251696 ns5:ShareCapital 2024-09-30 15251696 ns5:RetainedEarningsAccumulatedLosses 2025-09-30 15251696 ns5:RetainedEarningsAccumulatedLosses 2024-09-30 15251696 ns5:PlantMachinery 2024-09-30 15251696 ns5:PlantMachinery 2024-10-01 2025-09-30 15251696 ns5:PlantMachinery 2025-09-30 15251696 ns5:PlantMachinery 2024-09-30 15251696 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-09-30 15251696 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-09-30 15251696 ns5:DeferredTaxation 2024-09-30 15251696 ns5:DeferredTaxation 2024-10-01 2025-09-30 15251696 ns5:DeferredTaxation 2025-09-30 15251696 ns10:OrdinaryShareClass1 2025-09-30

REGISTERED NUMBER: 15251696 (England and Wales)

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2025

FOR

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED (REGISTERED NUMBER: 15251696) |

CONTENTS OF THE FINANCIAL STATEMENTS

For The Year Ended 30 September 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

| C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED |

COMPANY INFORMATION

For The Year Ended 30 September 2025

| DIRECTORS: | T Daffern

| Professor N S Scrutton FRS

| SECRETARY: | P Dennison ACA, FCCA

| REGISTERED OFFICE: | 20 Mannin Way

| Lancaster Business Park

| Caton Road

| Lancaster

| Lancashire

| LA1 3SW

| REGISTERED NUMBER: | 15251696 (England and Wales)

| SENIOR STATUTORY AUDITOR: | Rebecca Pickard FCCA

| AUDITORS: | TC Group, Statutory Auditor

| 1 Rushmills

| Bedford Road

| Northampton

| Northamptonshire

| NN4 7YB

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED (REGISTERED NUMBER: 15251696) |

BALANCE SHEET

30 September 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 247,429 |  | 154,857 |  |

CURRENT ASSETS

Debtors | 5 | 113,907 |  | 82,019 |  |

Cash at bank | 57,933 |  | 95,902 |  |

171,840 |  | 177,921 |  |

CREDITORS

Amounts falling due within one year | 6 | 86,708 |  | 137,604 |  |

NET CURRENT ASSETS | 85,132 |  | 40,317 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 332,561 |  | 195,174 |  |

PROVISIONS FOR LIABILITIES | 7 | 63,426 |  | 38,714 |  |

NET ASSETS | 269,135 |  | 156,460 |  |

CAPITAL AND RESERVES

Called up share capital | 8 | 100 |  | 100 |  |

Retained earnings | 269,035 |  | 156,360 |  |

SHAREHOLDERS' FUNDS | 269,135 |  | 156,460 |  |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 May 2026 and were signed on its behalf by:

Professor N S Scrutton FRS - Director

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED (REGISTERED NUMBER: 15251696) |

NOTES TO THE FINANCIAL STATEMENTS

For The Year Ended 30 September 2025

1. | STATUTORY INFORMATION

| C3 Biotechnologies (Acrylics) Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| There were no departures from that standard.

| The Company's functional and presentational currency is GBP. Monetary amounts in these financial statements are rounded to the nearest £.

| Significant judgements and estimates

| In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

| The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Revenue is recognised on long term contracts where the outcome of the contract can reliably be

| estimated. Revenue and costs are recognised based on the work performed at the date of the

| balance sheet. This is measured looking at the actual costs incurred to date. The estimated costs of a contract are based on detailed models of expected costs, which are regularly reviewed as the project progresses. Adjustments to total expected costs are updated as required.

| Tangible fixed assets

| Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Scientific equipment |  | Straight line over 3 years |  |

| Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised within 'administrative expenses' in the statement of income and retained earnings.

| At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use.

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED (REGISTERED NUMBER: 15251696) |

NOTES TO THE FINANCIAL STATEMENTS - continued

For The Year Ended 30 September 2025

2. | ACCOUNTING POLICIES - continued

| Financial instruments

| Basic financial assets, including trade and other receivables and cash and bank balances, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortised cost using the effective interest method.

| At the end of each reporting period financial assets measured at amortised cost are assessed forobjective evidence of impairment. If an asset is impaired the impairment loss is the differencebetween the carrying amount and the present value of the estimated cash flows discounted at theasset’s original effective interest rate. The impairment loss is recognised in profit or loss.

| Financial assets are derecognised when (a) the contractual rights to the cash flows from the assetexpire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset aretransferred to another party or (c) despite having retained some significant risks and rewards ofownership, control of the asset has been transferred to another party who has the practical ability tounilaterally sell the asset to an unrelated third party without imposing additional restrictions.

| Basic financial liabilities, including trade and other payables, and loans from fellow groupcompanies, are initially recognised at transaction price, unless the arrangement constitutes afinancing transaction, where the debt instrument is measured at the present value of the futurereceipts discounted at a market rate of interest. Debt instruments are subsequently carried atamortised cost, using the effective interest rate method.

| Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

| Financial liabilities are derecognised when the liability is extinguished, that is when the contractual

| obligation is discharged, cancelled or expires.

| Financial assets and liabilities are offset and the net amounts presented in the financial statementswhen there is a legally enforceable right to set off the recognised amounts and there is an intentionto settle on a net basis or to realise the asset and settle the liability simultaneously.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED (REGISTERED NUMBER: 15251696) |

NOTES TO THE FINANCIAL STATEMENTS - continued

For The Year Ended 30 September 2025

2. | ACCOUNTING POLICIES - continued

| Research and development

| Expenditure on research and development is written off in the year in which it is incurred.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Going concern

| At the time of approving the financial statements, the directors have a reasonable expectation that the company, as also supported by fellow group companies, has adequate resources and funding in place to continue in operational existence for the foreseeable future and pay its liabilities as they fall due. Furthermore, the directors have prepared detailed financial forecasts including cash flow forecasts, based on the results of these, and the support noted above, they consider the company retains sufficient working capital to continue trading for the foreseeable future.

| The directors have considered the impact the current economic environment in relation to their assessment of going concern and in their opinion have taken all reasonable steps to mitigate these factors. As at the point of authorising the accounts, and for the foreseeable future, the directors consider the going concern assumption to still be appropriate. The directors acknowledge that given the currently rapidly changing business and social environment, there are likely to be significant unknown factors which may present themselves. Such factors are considered by the directors to represent a general inherent level of risk in relation to the going concern assumption albeit not quantifiable at this time.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was NIL (2024 - NIL).

4. | TANGIBLE FIXED ASSETS

| Scientific

| equipment

£ |

| COST

| At 1 October 2024 | 195,601 |  |

| Additions | 199,130 |  |

| Disposals | (8,365 | ) |

| At 30 September 2025 | 386,366 |  |

| DEPRECIATION

| At 1 October 2024 | 40,744 |  |

| Charge for year | 100,284 |  |

| Eliminated on disposal | (2,091 | ) |

| At 30 September 2025 | 138,937 |  |

| NET BOOK VALUE

| At 30 September 2025 | 247,429 |  |

| At 30 September 2024 | 154,857 |  |

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED (REGISTERED NUMBER: 15251696) |

NOTES TO THE FINANCIAL STATEMENTS - continued

For The Year Ended 30 September 2025

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Amounts owed by group undertakings | - |  | 100 |  |

| Tax | 78,555 |  | 50,271 |  |

| VAT | 33,018 |  | 24,783 |  |

| Prepayments and accrued income | 2,334 |  | 6,865 |  |

113,907 |  | 82,019 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 62,135 |  | 8,796 |  |

| Accruals and deferred income | 24,573 |  | 128,808 |  |

86,708 |  | 137,604 |  |

7. | PROVISIONS FOR LIABILITIES

2025 | 2024 |

£ | £ |

| Deferred tax | 63,426 |  | 38,714 |  |

| Deferred |

| tax |

£ |

| Balance at 1 October 2024 | 38,714 |  |

| Provided during year | 24,712 |  |

| Balance at 30 September 2025 | 63,426 |  |

8. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 100 | Ordinary | £1 | 100 |  | 100 |  |

9. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Rebecca Pickard FCCA (Senior Statutory Auditor)

| for and on behalf of TC Group, Statutory Auditor

10. | RELATED PARTY DISCLOSURES

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group..

C3 BIOTECHNOLOGIES (ACRYLICS) LIMITED (REGISTERED NUMBER: 15251696) |

NOTES TO THE FINANCIAL STATEMENTS - continued

For The Year Ended 30 September 2025

11. | ULTIMATE CONTROLLING PARTY

| The controlling party is C3 Biotechnologies Limited.

| The ultimate controlling party is the directors of C3 Biotechnologies Limited by virtue of their shareholdings.

| The registered office is 20 Mannin Way Lancaster Business Park, Caton Road, Lancaster, Lancashire, United Kingdom, LA1 3SW.